Yahoo Finance

Lepu Biopharma has granted ArriVent Exclusive License for MRG007, a Potential Best-in-Class ADC for the treatment of Gastrointestinal Cancers

HONG KONG, Jan. 22, 2025 /PRNewswire/ -- Today, Lepu Biopharma Co., Ltd (Stock Code: 02157.HK) announced that it has entered into an exclusive licensing agreement with ArriVent BioPharma, Inc. for ...

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted ...
Yahoo Finance

Adcendo ApS Completes $75 Million Series C Financing to Continue Advancing First- and Best-in-class Clinical ADC Pipeline

Oversubscribed financing led by Jeito Capital, including additional new investment from Vida Ventures, BPI France, and EIFO, with participation from all existing investors Proceeds to support the ...
EDN

Renesas’s Intersil Brand 14-Bit, 1-MSPS ADC Delivers Best-in-Class Radiation-Hardened Performance for Satellites, Manned Spacecraft, and Lunar Space Missions

Renesas Electronics Corporation, a premier supplier of advanced semiconductor solutions, today announced the industry’s highest-performance single-chip 14-bit, 1-MSPS successive-approximation-register ...
Morningstar

Jeito Capital leads oversubscribed $75 million Series C in Adcendo ApS to Advance its First- and Best-in-class Clinical ADC1 Pipeline in Oncology

Proceeds from the financing will support the advancement of three first- and best-in-class ADC programs through upcoming key clinical milestones While oncology continues to face substantial and ...
PharmiWeb

Adcendo ApS Announces Extension of Series A Financing to EUR 98M to Further Bolster its First-in-Class ADC Pipeline

Raises additional 16M EUR led by Dawn Biopharma, a platform controlled by KKR, with participation from existing investors Funds will be used to further strengthen growing pipeline of first in class ...
Pharmabiz

Immunome doses first patient in phase 1 trial to evaluate IM-1617, a potential first-in-class ADC in patients with advanced solid tumours

Immunome doses first patient in phase 1 trial to evaluate IM-1617, a potential first-in-class ADC in patients with advanced solid tumours: Bothell, Washington Monday, June 15, 202 ...